Veru/$VERU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Veru
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
Ticker
$VERU
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
210
ISIN
US92536C1036
Website
Veru Metrics
BasicAdvanced
$96M
-
-$0.25
-0.73
-
Price and volume
Market cap
$96M
Beta
-0.73
52-week high
$1.42
52-week low
$0.45
Average daily volume
3.4M
Financial strength
Current ratio
3.804
Quick ratio
3.562
Long term debt to equity
12.548
Total debt to equity
12.548
Interest coverage (TTM)
-67.46%
Profitability
EBITDA (TTM)
-40.755
Gross margin (TTM)
34.67%
Net profit margin (TTM)
-215.24%
Operating margin (TTM)
-242.68%
Effective tax rate (TTM)
-2.39%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-49.03%
Return on equity (TTM)
-93.86%
Valuation
Price to revenue (TTM)
5.681
Price to book
4.56
Price to tangible book (TTM)
6.78
Price to free cash flow (TTM)
-3.281
Free cash flow yield (TTM)
-30.48%
Free cash flow per share (TTM)
-19.98%
Growth
Revenue change (TTM)
134.43%
Earnings per share change (TTM)
-32.24%
3-year revenue growth (CAGR)
-34.64%
10-year revenue growth (CAGR)
-5.92%
3-year earnings per share growth (CAGR)
-10.61%
10-year earnings per share growth (CAGR)
8.73%
What the Analysts think about Veru
Analyst ratings (Buy, Hold, Sell) for Veru stock.
Veru Financial Performance
Revenues and expenses
Veru Earnings Performance
Company profitability
Veru News
AllArticlesVideos
Veru to Participate in the Virtual BTIG Obesity Health Forum
GlobeNewsWire·2 weeks ago
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
GlobeNewsWire·1 month ago
JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Veru stock?
Veru (VERU) has a market cap of $96M as of June 28, 2025.
What is the P/E ratio for Veru stock?
The price to earnings (P/E) ratio for Veru (VERU) stock is 0 as of June 28, 2025.
Does Veru stock pay dividends?
No, Veru (VERU) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Veru dividend payment date?
Veru (VERU) stock does not pay dividends to its shareholders.
What is the beta indicator for Veru?
Veru (VERU) has a beta rating of -0.73. This means that it has an inverse relation to market volatility.